The global pharmaceutical industry experienced a 51% drop in company filings mentions of future of work in Q3 2023 compared with the previous quarter, with the highest share accounted for by Dr. Reddy’s Laboratories with 1200% year-on-year increase, according to GlobalData’s analysis of over 405 pharmaceutical company filings. GlobalData’s Pharma: Filings Trends & Signals Q3 2023 report delves into earnings call transcripts and quarterly reports within the pharmaceuticals industry, extracting trends, signals, and comparative data to help businesses assess their performance, identify competitive intelligence, evaluate risks, and gain a comprehensive understanding of key industry events. Buy the report here.
Notably, future of work was one of the most frequently referenced themes in Q3 2023, ranking highest in terms of mentions, ahead of big data and individualism & expression, according to GlobalData.
Of the top leading companies in the pharmaceutical industry, Dr. Reddy's Laboratories had the greatest increase in references for future of work in Q3 2023, compared with the previous quarter. GlobalData identified 26 future of work-related sentences in the company's filings - 0.4% of all sentences - and an increase of 1200% in Q3 2023 compared with Q3 2022. CSL’s mentions of future of work rose by 22% to 11 and Biogen’s by 67% to 5 and Sun Pharmaceutical Industries’s by 29% to 5 and Cipla’s by 85% to 4.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for future of work in Q3 2023 was 91.
For further understanding of GlobalData's Pharma: Filings Trends & Signals Q3 2023, buy the report here.